Press coverage about OHR Pharmaceutical (NASDAQ:OHRP) has trended positive recently, AlphaOne Sentiment reports. The research firm, a service of Accern, ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OHR Pharmaceutical earned a news sentiment score of 0.31 on AlphaOne’s scale. AlphaOne also assigned news headlines about the biotechnology company an impact score of 100 out of 100, indicating that recent news coverage is extremely likely to have an effect on the company’s share price in the next few days.

These are some of the news headlines that may have impacted AlphaOne Sentiment’s scoring:

Separately, HC Wainwright set a $10.00 price objective on OHR Pharmaceutical and gave the stock a “buy” rating in a research note on Friday, February 17th.

Shares of OHR Pharmaceutical (OHRP) traded up 1.59% during mid-day trading on Friday, hitting $0.64. The stock had a trading volume of 31,500 shares. The stock’s 50-day moving average price is $0.66 and its 200-day moving average price is $1.20. OHR Pharmaceutical has a 12-month low of $0.60 and a 12-month high of $4.05. The stock’s market capitalization is $35.98 million.

OHR Pharmaceutical (NASDAQ:OHRP) last issued its earnings results on Thursday, May 11th. The biotechnology company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.09. On average, equities analysts anticipate that OHR Pharmaceutical will post ($1.00) EPS for the current fiscal year.

In other OHR Pharmaceutical news, CFO Samuel Backenroth bought 71,429 shares of the company’s stock in a transaction on Monday, April 10th. The stock was bought at an average price of $0.70 per share, for a total transaction of $50,000.30. Following the transaction, the chief financial officer now owns 212,596 shares of the company’s stock, valued at approximately $148,817.20. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Orin Hirschman purchased 142,858 shares of the firm’s stock in a transaction dated Monday, April 10th. The stock was purchased at an average cost of $0.70 per share, with a total value of $100,000.60. The disclosure for this purchase can be found here. Insiders own 17.70% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at

Receive News & Ratings for OHR Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.